Upcoming webinar

The ctDNA signal: Rethinking how we monitor immunotherapy response

Date: Friday, October 30, 2026

Time: 12:00 PM PT (30-minute webinar)

Registrants will receive a recording of the webinar approximately one week after the event.

Oncologists need a tool that tells them sooner whether a regimen is working, before a costly, and possibly ineffective treatment decision gets made.

Signatera™ is a personalized ctDNA assay that works broadly as a real-time treatment response biomarker, sensitive enough to pick up small shifts in disease burden that precede imaging changes.

Join our information webinar where our experts will discuss:

How an earlier signal of non-response may provide an opportunity to switch therapy sooner, potentially sparing patients from toxicity of a regimen that isn't working
Review the IMvigor011 data in bladder cancer where ctDNA-positive patients treated with atezolizumab had meaningfully better DFS and OS than those on observation
Continued validation with the EMPower Lung data, reinforcing the pan-tumor application
Learn more about the SIGNAL platform specifically designed to generate interventional evidence for ctDNA-guided treatment decisions to evolve the pan-cancer IO monitoring story

Natera Honey Pot

Register Now:

First Name*

Last Name*

Email Address*

Job Title*

Phone*

Company Name*

Postal Code*

Country*

I am a*

Do you have any questions for the presenters that you would like to submit before the webinar?

Please fill in the field above only if you have specific questions. Otherwise, leave it blank.

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time.

Hear from our speakers:

Dr. Leo Shunyakov

Oncologist Hematologist

Citizens Memorial Hospital

Dr. Leo Shunyakov specializes in various cancers including lymphomas, leukemia, breast, colon, lung, melanoma as well as malignant blood disorders. He serves as a member of the American Society of Clinical Oncology, the American Society of Hematology, the Missouri State Medical Association and the American Medical Association.

Caitlin Schonewolf, MD, MS

Sr. Medical Director

Oncology, Natera

Pinal Chokshi

Area Medical Director

General Oncology, Natera

Signatera™ has been developed and its performance characteristics determined by the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the US Food and Drug Administration (FDA). CAP accredited, ISO 13485 certified, and CLIA certified. © 2026 Natera, Inc. All Rights Reserved.

13011 McCallen Pass, Building A Suite 100 | Austin, TX 78753 | natera.com | Do Not Share My Personal Information | Privacy Policy